Beijing, China, 10 Dec – Companies from Brazil and China plan to jointly manufacture the latest medications, as part of a technology transfer deal signed Wednesday in Beijing.
The agreement, signed by EMS and two Shanghai laboratories (Biomabs and Guojian), is part of the Brazilian effort to “develop he pharmaceutical industry” and relieve Brazil’s “high dependence” in this area, said Brazil’s health minister, José Gomes Temporão.
The first product of the new partnership, which will be manufactured in Brazil within five years, is Etanercept, a drug mainly used to treat rheumatoid arthritis, a disease that affects some 850,000 Brazilians.
The agreement which, according to its signatories, will be a “technological platform,” also includes production of a further five drugs known as monoclonal antibodies.
Founded 45 years ago EMS is considered to be the biggest pharmaceutical company in Brazil.
The Brazilian Health Minister is in Beijing as part of a six-day visit to China to promote bilateral cooperation in the pharmaceutical sector and his delegation includes five sector associations, representing over 300 companies, as well as officials from state bank Banco Nacional de Desenvolvimento Económico e Social and other public bodies. (macauhub)